Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
China Animal Husbandry Industry Co., Ltd. (600195.SS)
CNY6.52
+0.27 (+4.32%)
CN SHH Healthcare Drug Manufacturers - Specialty & Generic
Address
Building 16-19 100070
Beijing, CN
Beijing, CN
CEO
Yin Li
Website
cahic.com
IPO
1999-01-07
ISIN CNE000000Y03
Description
China Animal Husbandry Industry Co., Ltd. operates within China, specializing in the development, manufacturing, and sale of products designed for animal health and nutrition. Its comprehensive range includes veterinary pharmaceuticals, vaccines, and other biological remedies for animals, as well as various feed products and nutritional additives. The company also engages in the trading of raw materials. Established in 1998, its corporate headquarters are situated in Beijing, China.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY6.52
+0.27 (+4.32%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
15M
Beta
0.30
Float Shares
499.40M
Free Float %
48.9%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.95% | -0.95% | -7.51% | -5.22% | -9.46% | -7.62% | +6.75% | -45.05% | -35.44% | -1.09% | +147.28% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
6.52
DCF (Unlevered)
4.56
-30.1%
DCF (Levered)
25.83
+296.1%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 4 | 0 |
| Buy | 4 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
2.94
Grey zone
Piotroski F-Score
6 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
B-
Overall Score
3 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+3.1% Q1'26: +19.9% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+145.0% ★ Q1'26: -62.2% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+14.7% ★ Q1'26: -23.6% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+1.1% Q1'26: +6.1% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+1.1% Q1'26: +3.6% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%0.0% ★ Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×1.87× ★ Q1'26: 2.72× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 3 Rev. Ana. 3 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
4.23B
est: 5.09B (-16.8%)
|
3.97B
est: 3.95B (+0.7%)
|
4.07B
est: 4.12B (-1.1%)
|
4.43B
est: 4.73B (-6.3%)
|
4.14B
est: 4.17B (-0.7%)
|
5.00B
est: 4.73B (+5.7%)
|
5.30B
est: 5.80B (-8.7%)
|
5.89B
est: 5.75B (+2.5%)
|
5.41B
est: 5.38B (+0.5%)
|
6.02B
est: 5.09B (+18.3%)
|
6.20B
est: 6.68B (-7.1%)
|
7.18B
6.59B – 7.48B
+7.5% YoY
|
7.76B
6.60B – 8.36B
+8.1% YoY
|
| EBITDA |
456.82M
est: 522.85M (-12.6%)
|
451.75M
est: 405.44M (+11.4%)
|
426.04M
est: 422.72M (+0.8%)
|
506.63M
est: 485.97M (+4.3%)
|
364.45M
est: 427.83M (-14.8%)
|
539.77M
est: 485.92M (+11.1%)
|
752.93M
est: 596.22M (+26.3%)
|
646.28M
est: 590.56M (+9.4%)
|
506.58M
est: 506.93M (-0.1%)
|
362.24M
est: 479.46M (-24.4%)
|
407.85M
est: 629.35M (-35.2%)
|
676.72M
621.61M – 705.46M
+7.5% YoY
|
731.59M
622.31M – 788.57M
+8.1% YoY
|
| EBIT |
294.83M
est: 282.68M (+4.3%)
|
274.81M
est: 219.20M (+25.4%)
|
245.71M
est: 228.54M (+7.5%)
|
338.38M
est: 262.74M (+28.8%)
|
181.47M
est: 231.31M (-21.5%)
|
351.47M
est: 262.71M (+33.8%)
|
503.69M
est: 322.34M (+56.3%)
|
384.80M
est: 319.29M (+20.5%)
|
213.12M
est: 234.61M (-9.2%)
|
45.87M
est: 221.90M (-79.3%)
|
66.90M
est: 291.27M (-77.0%)
|
313.19M
287.69M – 326.50M
+7.5% YoY
|
338.59M
288.01M – 364.96M
+8.1% YoY
|
| Net Income |
275.67M
est: 299.85M (-8.1%)
|
334.42M
est: 318.68M (+4.9%)
|
399.87M
est: 354.60M (+12.8%)
|
415.63M
est: 441.08M (-5.8%)
|
249.37M
est: 385.41M (-35.3%)
|
420.43M
est: 520.79M (-19.3%)
|
513.86M
est: 551.42M (-6.8%)
|
550.07M
est: 561.93M (-2.1%)
|
403.05M
est: 196.89M (+104.7%)
|
70.88M
est: 159.21M (-55.5%)
|
171.32M
est: 169.17M (+1.3%)
|
202.00M
196.27M – 231.62M
+19.4% YoY
|
333.40M
209.71M – 371.76M
+65.1% YoY
|
| SGA |
749.71M
est: 677.69M (+10.6%)
|
841.77M
est: 525.51M (+60.2%)
|
707.97M
est: 547.91M (+29.2%)
|
729.45M
est: 629.89M (+15.8%)
|
723.08M
est: 554.54M (+30.4%)
|
718.59M
est: 629.83M (+14.1%)
|
809.07M
est: 772.79M (+4.7%)
|
694.93M
est: 765.46M (-9.2%)
|
676.05M
est: 707.24M (-4.4%)
|
760.23M
est: 668.92M (+13.7%)
|
841.67M
est: 878.04M (-4.1%)
|
944.13M
867.24M – 984.22M
+7.5% YoY
|
1.02B
868.22M – 1.10B
+8.1% YoY
|
| EPS |
0.27
est: 0.29 (-7.0%)
|
0.33
est: 0.31 (+5.7%)
|
0.40
est: 0.35 (+14.0%)
|
0.41
est: 0.43 (-5.1%)
|
0.25
est: 0.38 (-34.6%)
|
0.41
est: 0.51 (-18.7%)
|
0.51
est: 0.54 (-6.3%)
|
0.54
est: 0.55 (-1.5%)
|
0.39
est: 0.19 (+104.7%)
|
0.07
est: 0.16 (-56.6%)
|
0.17
est: 0.17 (+0.0%)
|
0.22
0.19 – 0.23
+26.5% YoY
|
0.31
0.21 – 0.36
+41.9% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-11 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-08 | C+ | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-07 | C+ | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-06 | C+ | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-30 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-29 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-28 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-27 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-22 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-21 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-20 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-17 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-16 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
1.08B
OE per share TTM
1.06
Owner's Yield
14.35%
Maintenance CapEx ratio
336.48%
Maint CapEx / Avg PPE
51.8%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 22 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 117.7K | 0.39% |
| 2 | Vanguard FTSE All-World UCITS ETF (USD) Distributing VWRD.L | 0.00% | 767.4K | 0.19% |
| 3 | Vanguard FTSE All-World UCITS ETF (USD) Accumulating VWRA.L | 0.00% | 767.4K | 0.19% |
| 4 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 71.5K | 0.29% |
| 5 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 8.0K | 0.48% |
| 6 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 18.0K | 0.26% |
| 7 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 888.0K | 0.06% |
| 8 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 62.2K | 0.28% |
| 9 | Vanguard Total World Stock ETF VT | 0.00% | 243.8K | 0.06% |
| 10 | Vanguard All-World ex-US Shares Index ETF VEU.AX | 0.00% | 7.6K | 0.04% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
15.6K
Shares Outstanding
1.02B
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jie Jiao | Deputy GM & Secretary | — | female |
| Xinyan Zhang | Chief Accountant | — | female |
| Yin Li | GM & Director | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 600195.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
